Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Simplifies Mobile Payments with O2O Commerce Marketplace

A recent Global Mobile Money Report by Nielsen (http://dtn.fm/7rflL) shows that almost half of Chinese consumers will likely use a mobile device to make payments in restaurants, bars and retail stores—a much higher number than among consumers in the United States and Europe. Cashing in on China’s cashless trend and having recently upgraded its mobile payments capability, Moxian, Inc. (NASDAQ: MOXC) is doing business at the confluence of online retail and brick-and-mortar establishments, operating an online platform that utilizes social media to drive business to small and medium-sized enterprises (SMEs).

An article further discussing this reads: “In early 2017, the company announced the launch of a new version of its Moxian User App and Business App (New Version Apps) that feature built-in UnionPay payment modules. This follows the company’s strategic partnership with Beijing Chinaums, a subsidiary of China UnionPay, in December 2016. This seamless integration of Moxian’s proprietary virtual currency engine and UnionPay’s powerful payment gateway will allow users (merchants and shoppers) of the New Version Apps to process payments through UnionPay’s payment gateway, which also supports payments from Alipay and WeChat Pay. The UnionPay payment gateway also meshes seamlessly with Moxian’s MO-Coin and MO-Point system, which rewards customers who use and process payments with the New Version Apps. The Moxian Software Machine also tracks customer behavior, which in turn allows Moxian to provide the participating merchants with complete and detailed analytic data and tools. Merchants on the Moxian Marketplace can study the behavior of their customers and respond with precise targeted marketing campaigns.”

To view the full article, visit http://dtn.fm/Dub3f

About Moxian, Inc.

Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Moxian Inc. MOXC | Leave a comment

India Globalization Capital, Inc. (NYSE: IGC) Preparing to Bring Cannabis Combo Therapy for Alzheimer’s Disease to Trials

  • Four drug candidates in the pipeline
  • Potential sales of Alzheimer’s drugs run to billions
  • Hyalolex heading for clinical trials

India Globalization Capital, Inc. (NYSE MKT: IGC) is racing ahead with its preparation of medical trials for four drug candidates that treat a variety of debilitating conditions. At the head of the line is Hyalolex, aimed at reducing the buildup of amyloid β-peptide (Aβ) plaques on neurons in the brain, a process that causes the crippling cognitive complaint known as Alzheimer’s disease.

Alzheimer’s afflicts more than five million Americans, and, so far, no effective cure for this form of dementia has been found. However, the FDA has approved five medications to treat its symptoms. IGC is hoping to make Hyalolex the sixth. The drug works through a molecular pathway that allows low doses of THC to bind to Aβ plaques and so prevent them from aggregating on neurons. IGC has entered into a definitive license agreement (http://dtn.fm/7Xsmp) with the University of South Florida (USF), which makes IGC the exclusive licensee of the USF-developed technology that is the subject of a U.S. patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” If approved, Hyalolex could go some way to reducing the costs of treating Alzheimer’s, estimated to reach $259 billion in 2017. It should also bring IGC’s market cap in line with peer valuations that range in the hundreds of millions.

Alzheimer’s has the unwelcome distinction of being number five on the list of America’s five most deleterious diseases, after heart disease, cancer, chronic lower respiratory conditions and strokes, according to the Centers for Disease Control and Prevention (CDC). Every minute, someone new develops the condition, which takes its toll not just on those afflicted but on caregivers. The Alzheimer’s Association says that ‘35% of caregivers for people with Alzheimer’s or another dementia report that their health has gotten worse due to care responsibilities, compared to 19% of caregivers for older people without dementia”. The economic cost is also staggering and, if no cure or palliative is found soon, is expected to exceed $1 trillion by 2050.

With such high stakes, IGC’s pioneering therapy has become vitally important. Its mechanism of action uses the psychotropic component of cannabis, Δ9-tetrahydrocannabinol (THC), to inhibit the enzyme acetylcholinesterase (AChE) and prevent the aggregation of AChE-induced amyloid β-peptide (Aβ), which is the key pathological marker of Alzheimer’s disease.

Current treatments authorized for sale to the public by the U.S. Food and Drug Administration (FDA) for Alzheimer’s include donepezil, approved in 1996; galantamine (2001); rivastigmine (2000); memantine (2003); and a combination of donepezil and memantine, approved in 2014. Sales of donepezil (Aricept) reached $3.5 billion in 2009, the year before its generics were allowed market entry. Sales of rivastigmine (Exelon) have been in the hundreds of millions, exceeding $1.0 billion in 2011, and sales of memantine (Namenda) continue annually above $1.0 billion. According to Mordor Intelligence, “the global Alzheimer’s’ disease market… due to drug patent expirations in 2017 and many generics entering the market… is expected to see a declination… by the year 2017. (On the other hand), the market is anticipated to grow driven by… last-stage pipeline drugs”. They might have added “like Hyalolex.”

IGC’s pipeline also includes Natrinol, a natural substitute for Marinol, or synthetic THC, aimed at relieving nausea and vomiting while increasing appetite in patients with AIDS and cancer; Caesafin, which uses combination therapy to alleviate seizures in dogs and cats; and Serosapse, which addresses several end-points in Parkinson’s disease, including rapid eye movement (REM) sleep disorder, anxiety and dyskinesia.

For more information, visit the company’s website at www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in India Globalization Capital, Inc. IGC | Leave a comment

Moxian, Inc. (NASDAQ: MOXC) Shareholders to Vote on Seven Directors at Annual Meeting on September 29 in Beijing

  • Director nominees include Liu Shu Juan, CEO of Shewn International Group and financial controller of Shanghai Shewn Wine Co.
  • Moxian is expected to formalize joint venture agreement with Shewn International Group by end of September 2017
  • Joint ventures are part of Moxian’s new strategy to enter major markets in China more quickly and at lower cost

Moxian, Inc. (NASDAQ: MOXC) will nominate seven directors to its board for shareholders at its annual meeting on September 29, 2017, in Beijing, China (http://dtn.fm/y8lBO). Among the seven is Liu Shu Juan, chief executive officer of Shewn International Group, Inc. and financial controller of Shanghai Shewn Co., Ltd., the company’s primary operator in China.

Liu has been a Moxian board member since August 2017. Moxian has an agreement of understanding with Shewn International Group, Inc., expected to be finalized by the end of September 2017, for a joint venture as part of a new marketing strategy for Moxian. The Shanghai-based company plans a series of joint ventures to enable it to penetrate key markets in China more quickly and at a lower cost. James Mengdong Tan, president and chief executive officer of Moxian, told Crystal Equity Research that he has some opportunities for 30-40 companies in the pipeline for future joint ventures.

Moxian is an integrated platform operator focused on processing digital payments and converting its Moxian+ Merchant and Moxian+ User apps to paid. It has a module on its Moxian+ Merchant platform for UnionPay, the dominant digital payment processor in China. That module makes joint ventures with Moxian attractive to other businesses.

Crystal Equity Research endorses the new joint venture strategy, citing its planned effectiveness and cost cutting in Moxian’s entry into new markets. Crystal Equity has projected that Moxian will achieve sales of $2.3 million by FY2018. It also notes that the joint venture provides Moxian with a new revenue stream, giving it a percentage of Shewn’s sales processed through the Moxian+ UnionPay app.

Additionally, the joint venture is an effective way of having Moxian gain quicker entry into new markets within China at a lower price. Crystal Equity Research said that Moxian’s cash burn rate was only $1.3 million in the quarter ended June 2017 versus $5.4 million in the prior quarter. Shewn markets fine wines in China and plans to use Moxian’s relationship and app for payments through UnionPay. It is also planning to market its wines into luxury complexes through as many as 500,000 new specialized vending machines.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Moxian Inc. MOXC | Leave a comment

MissionIRNewsBreaks – Monaker Group, Inc. (MKGI) CEO to Present at Robins Equity Research Roundup

Travel and technology company Monaker Group, Inc. (OTCQB: MKGI) this morning announced that it has been invited to present at the Third Annual Robins Equity Research Roundup, which is scheduled to take place September 26-27 at the Shilo Inn and Suites in Portland, Oregon. Monaker CEO Bill Kerby is scheduled to present on Tuesday, September 26 at 11:15 a.m. Pacific Time. He will be joined by Richard Marshall, the company’s director of corporate development, for one-on-one meetings with institutional analysts and investors on that same day. Kerby’s presentation is expected to focus on the Monaker Booking Engine (MBE), a new cloud-based technology platform that delivers ALR reservations that can be instantly confirmed. As the company noted in a news release earlier this month, the MBE platform is currently approaching its first commercial launch by a “major travel industry partner.”

To view the full press release, visit http://dtn.fm/I48iH

About Monaker Group

Monaker Group is a technology-driven travel company focused on delivering innovation to alternative lodging rentals (ALR) market. The Monaker Booking Engine (MBE) delivers instant booking of more than 1.4 million vacation rental homes, villas, chalets, apartments, condos, resort residences and castles. MBE offers travel distributors and agencies an industry-first: a customizable, instant-booking platform for alternative lodging. For more information, visit www.monakergroup.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Monaker Group Inc. MKGI | Leave a comment

Moxian, Inc. (NASDAQ: MOXC) O2O Commerce Marketplace Makes Mobile Payments Easier

  • Provider of mobile payment tools
  • Using social media to drive ecommerce
  • Marketplace that links offline and online

A look at Nielsen’s latest Global Mobile Money Report (http://dtn.fm/C8SXf) shows that Moxian, Inc. (NASDAQ: MOXC) is in the right place at the right time. The Nielsen report shows that close to half of Chinese consumers are likely to use a mobile device to pay their bills in bars, restaurants and retail stores, a far, far higher number than in the U.S. or Europe. This revealing statistic, coupled with Moxian’s position at the nexus of online retail establishments and their brick-and-mortar counterparts, gives the tech company a bet on both ecommerce and traditional retailing. The company, based in mainland China, operates an online platform that uses the drawing power of social media to drive business to small and medium-sized enterprises (SMEs). Now, with its capability to handle mobile payments recently upgraded, Moxian is likely to see its bets on O2O commerce pay off handsomely in the near future.

Although, at present, global online sales are still only about 10 percent of overall retail sales, its trend has been ever upward. Moreover, that global average hides some eye-opening detail. While in North America and Western Europe online accounted for 7.7 percent and 8.2 percent of the overall retail market in 2016, respectively, the retail market in China is running at around 12 percent of total consumer sales, according to data reported by Deloitte (http://dtn.fm/2ldKN). In 2015, total retail sales of consumer goods in China were valued at $4.61 trillion, which puts online retail in China at around $553 billion, a mind-boggling level of exchange that surpasses the national income of 191 countries of the 211 recognized by the United Nations as sovereign states.

Already, many of these online transactions are being initiated through mobile devices, with some analysts estimating that, in China, mobile accounts for around three-quarters of all online payments. A study by the Financial Times, reported by NPR (http://dtn.fm/Q083n), says that the ‘Chinese spent $5.5 trillion through mobile payment platforms last year, about 50 times the amount in the U.S.’ So powerful is the trend to mobile in this country of 1.3 billion, some commentators are suggesting (http://dtn.fm/dSS9j) that ‘China… the first country in the world to use paper money… (may) be the first to stop. In Beijing it is hard to find a product or a service that cannot be purchased with a mobile.’

Moxian is cashing in on this cashless trend. In early 2017, the company announced the launch of a new version of its Moxian User App and Business App (New Version Apps) that feature built-in UnionPay payment modules. This follows the company’s strategic partnership with Beijing Chinaums, a subsidiary of China UnionPay, in December 2016.

This seamless integration of Moxian’s proprietary virtual currency engine and UnionPay’s powerful payment gateway will allow users (merchants and shoppers) of the New Version Apps to process payments through UnionPay’s payment gateway, which also supports payments from Alipay and WeChat Pay. The UnionPay payment gateway also meshes seamlessly with Moxian’s MO-Coin and MO-Point system, which rewards customers who use and process payments with the New Version Apps. The Moxian Software Machine also tracks customer behavior, which in turn allows Moxian to provide the participating merchants with complete and detailed analytic data and tools. Merchants on the Moxian Marketplace can study the behavior of their customers and respond with precise targeted marketing campaigns.

Moxian is out to make smartphone payments while shopping easier for the Chinese consumer, whether buying online or at a favorite bazaar. For the merchant, the company provides access to the latest, most sophisticated marketing tools. As China ditches cash, the Moxian O2O Marketplace looks set to continue blurring the line between offline and online commerce.

For more information, visit the company’s website at www.Moxian.com

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Moxian Inc. MOXC | Leave a comment

India Globalization Capital, Inc. (NYSE: IGC) Reports Promising Progress of Cannabis-Based Alzheimer’s Drug Candidate

  • IGC is the only publicly traded cannabis stock with patent filings for treating Alzheimer’s disease
  • Company has a first-mover advantage in phytocannabinoid-based combination therapy
  • Alzheimer’s is America’s most expensive disease, costing the country an estimated $259 billion in 2017

It is considered America’s most expensive disease, projected to cost an estimated $259 billion in the United States in 2017 and as much as $1.1 trillion by 2050 (http://dtn.fm/2UWLl). It is not cancer, and it is not AIDS. It is Alzheimer’s disease.

This devastating chronic neurodegenerative disease is the most common cause of dementia among older adults and is the sixth-leading cause of death in the U.S. There is currently no cure for Alzheimer’s disease, nor are there presently any effective treatments to slow the disease or reverse its effects, but India Globalization Capital, Inc. (NYSE MKT: IGC) is working to change that.

In a recent press release (http://dtn.fm/5qvM2), IGC discussed its progress on IGC-ADI, a drug candidate that is cannabis-based and targeted at lessening some of Alzheimer’s worst symptoms. IGC-ADI works through a molecular pathway that permits low doses of tetrahydrocannabinol (THC) to do five things:

  1. Inhibit Aβ protein production
  2. Inhibit Aβ protein aggregation
  3. Reduce protein phosphorylation
  4. Restore mitochondria function
  5. Redirect the immune system

Amyloid beta peptide (Aβ) is a protein believed to cause the formation of plaque in the cerebral cortex and hippocampus, causing lesions. Alzheimer’s disease is believed to be caused by two different types of lesions—the first being senile plaque that is made up of amyloid beta peptides (Aβ plaque) and the second being neurofibrillary tangle, which is composed of highly phosphorylated Tau protein.

Aβ proteins are normally cleared away through biological processes, but, in Alzheimer’s patients, these proteins are unregulated and build up into insoluble fibroles. Senile plaques and extracellular misfolded oligomers resultantly form and are believed to be toxic to nerve cells in the brain. It has been found that IGC-AD1 may inhibit the production of amyloid beta peptide.

In a recent press release, IGC provided an update on in vitro data compiled from genetically engineered cell lines, which has been confirmed by IGC Senior Advisor Dr. Chuanhai Cao, who is also an associate professor of pharmaceutical sciences at the University of South Florida’s College of Pharmacy. The data shows that at varying THC concentrations, production of Aβ40 protein decreases by as much as 50 percent over a 48-hour time period.

Aβ40 and Aβ42 play a central role in amyloid plaques and have been implicated in the pathogenesis of Alzheimer’s disease. Dr. Cao’s studies at USF led to the filing of a patent by USF entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” IGC has since acquired the exclusive rights to the patent filing, and the company intends to advance the technology through medical trials, with the ultimate aim of bringing relief to Alzheimer’s sufferers.

IGC is currently the only publicly traded cannabis stock to have patent filings for a potential breakthrough Alzheimer’s treatment. This gives the company a first-mover advantage in phytocannabinoid-based combination therapy, as discussed in a recently published article featuring IGC and four other standout companies that are currently seeking to find viable treatments for Alzheimer’s (http://dtn.fm/9YfF0).

For more information, visit the company’s website at www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in India Globalization Capital, Inc. IGC | Leave a comment

MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on Data Showing Effectiveness of THC in Addressing Underlying Cause of Alzheimer’s

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model. Per the update, the aggregation of Aβ protein in the cerebral cortex and hippocampus, which is believed to be a primary cause of Alzheimer’s disease, is decreased by as much as 40 percent when treated with varying concentrations of THC. “As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss,” Ram Mukunda, CEO of IGC, stated in the news release. “These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50%, and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease.” Based on these findings, IGC intends to position IGC-AD1 as a drug that can be used both as a treatment for Alzheimer’s and as a prophylactic treatment for the prevention of Alzheimer’s. The company intends to commercialize a supplement version of IGC-AD1 to be sold as a medical dispensary product.

To view the full press release, visit http://dtn.fm/9qG5o

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in India Globalization Capital, Inc. IGC, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Modifies JV Approach to Enter Strategic Markets in China

In an effort to expand more rapidly in China, Moxian, Inc. (NASDAQ: MOXC) has shifted the focus of its joint venture strategy, including the agreement with Shewn International Group of Shanghai. An excerpt of an article further discussing this topic reads: “Moxian, Inc. has changed its business strategy to grow more quickly within China, targeting the nation’s top four markets while also beginning to utilize a joint venture strategy in order to penetrate these markets more efficiently with the aid of entrenched businesses. MOXC’s marketing and sales team members are now acting as sales managers, working with independent agents to secure higher volume.”

To view the full article, visit: http://dtn.fm/M9PoR

About Moxian, Inc.

Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the company can be found at www.moxian.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Moxian Inc. MOXC | Leave a comment

India Globalization Capital, Inc. (NYSE: IGC) Announces Alzheimer’s Drug Candidate Targeting Aβ Proteins

  • More than 5.3 million people in the U.S. have Alzheimer’s disease, which has no effective cure or substantial treatment
  • India Globalization Capital’s IGC-ADI drug candidate targets proteins associated with the buildup of lesions in the brain
  • The company acquired exclusive rights to a patent, based on University of South Florida studies supporting THC’s role in inhibiting Aβ plaque production

Alzheimer’s disease now affects over 5.3 million people in the United States, imposing an estimated economic cost of $236 billion. There has been no effective treatment to slow down or reverse its effects. That may be about to change, as India Globalization Capital, Inc. (NYSE MKT: IGC) launched a press release (http://dtn.fm/w01OQ) detailing its work on a drug candidate, IGC-ADI, that targets the buildup of lesions in the brain associated with Alzheimer’s. Given that the number of cases is expected to double over the next two decades, a lack of a cure or other mitigating therapy is concerning. However, the company expects to soon begin trials that may yield promising new treatments.

The unconventional nature of this drug candidate is that it is tetrahydrocannabinol (THC)-based. Low doses of THC have been found to inhibit amyloid beta peptide (Aβ plaque) production. This protein is believed to cause plaque to form in the cerebral cortex and hippocampus. Phosphorylated Tau proteins make up another type of lesion, called a neurofibrillary tangle, that is also linked to AD. The Aβ proteins normally cleared away by biological processes are unregulated in Alzheimer’s patients, and therefore build up into insoluble fibroles. The result is the formation of senile plaques and extracellular misfolded oligomers that are thought to be toxic to nerve cells in the brain.

Now the only publicly traded pharmaceutical cannabis stock that addresses the disease, IGC has developed a drug that inhibits protein production and protein aggregation and reduces the phosphorylation of protein, as explained in the recent Brand Awareness Distribution article, “Alzheimer’s Disease: Cannabis Formulation Shows Promise”. The drug candidate IGC-ADI is believed to also have the potential to restore mitochondria function and redirect the immune system. Studies on genetically engineered cell lines conducted at the University of South Florida (USF) have provided supportive evidence for the company to move forward. At THC concentrations of 25nM, Aβ40 production was cut by 30 percent over a six-hour period, and by 35 percent over 24 hours. When doses of 2.5 μM were introduced, amyloid beta peptide production was reduced by the same level at six hours, 40 percent over 24 hours, and 55 percent over 48 hours (compared to 40 percent at lower THC concentrations).

The patent “THC as a Potential Therapeutic Agent for Alzheimer’s Disease,” was filed based on the findings of the USF studies conducted by Dr. Chuanhai Cao, an Associate Professor of Pharmaceutical Sciences at USF’s College of Pharmacy and an IGC Senior Advisor. Expected to conduct human medical trials, IGC has already acquired exclusive rights to the patent filing, allowing it to use and advance the technology to find potential treatments for Alzheimer’s patients.

IGC-ADI is one of six patents involving cannabis-based combination therapy, providing investors with opportunities to help support potentially revolutionary treatments for Alzheimer’s, epilepsy, Parkinson’s disease, depression and post-traumatic stress disorder.

For more information, visit the company’s website at www.IGCInc.us

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in India Globalization Capital, Inc. IGC | Leave a comment

MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on Data Linking THC to Decrease in Aβ40 Protein Production

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced compelling in vitro data compiled from genetically engineered cell lines showing that, at varying concentrations of THC, the production of Aβ40 protein decreases by as much as 50 percent over a 48-hour period. This is particularly noteworthy for patients with Alzheimer’s disease, as the condition often results in an imbalance of Aβ plaque that is believed to be toxic to nerve cells. This data, compiled by Dr. Chuanhai Cao, an IGC senior advisor and associate professor of pharmaceutical studies at USF’s College of Pharmacy, led to the filing of a patent by USF entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” In the news release, Ram Mukunda, CEO of IGC, stated, “IGC acquired the exclusive right to this patent filing and we plan to advance this technology through medical trials that can potentially bring much needed relief for patients suffering from AD.”

To view the full press release, visit http://dtn.fm/scAZ5

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in India Globalization Capital, Inc. IGC, MissionIRNewsBreaks | Leave a comment